echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Taiji Group Caffeine Citrate Injection Obtained Drug Registration Certificate

    Taiji Group Caffeine Citrate Injection Obtained Drug Registration Certificate

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 26, Taiji Group issued an announcement stating that recently, its holding subsidiary, Southwest Pharmaceutical Co.


    The indications are: for the treatment of primary apnea in premature newborns.


    Caffeine citrate injection is a Class B drug in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Catalog (2020 Edition)".


    According to statistics from the "Menet" database, the total sales of the drug in Chinese urban public hospitals in 2019 were about 229.


    Up to now, the cumulative investment in research and development of this product is about 6.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.